Hydroxychloroquine Delays Disability for Least Treatable Form of Multiple Sclerosis

Hydroxychloroquine shows promise for reducing some of the debilitating systems associated with primary progressive multiple sclerosis, a new study reports. A University of Calgary study…

View More Hydroxychloroquine Delays Disability for Least Treatable Form of Multiple Sclerosis

Cabozantinib Shows Promise for Renal Cell Carcinoma With Brain Metastases

Cabozantinib yields promising intracranial activity with an acceptable safety profile for patients who developed brain metastases from renal cell carcinoma (RCC), according to study results…

View More Cabozantinib Shows Promise for Renal Cell Carcinoma With Brain Metastases

Methylphenidate Safe and Effective in Reducing Apathy in Alzheimer Disease

Methylphenidate, the most widely studied catecholaminergic compound in older adults, is safe and may have modest but noticeable benefits on apathy in patients with Alzheimer…

View More Methylphenidate Safe and Effective in Reducing Apathy in Alzheimer Disease

Long-Term Satralizumab Safe in Patients with Neuromyelitis Optica Spectrum Disorder

The following article is part of conference coverage from the 2021 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), held October 25-28 2021, in…

View More Long-Term Satralizumab Safe in Patients with Neuromyelitis Optica Spectrum Disorder

Ocrelizumab Beneficial for Relapse Risk and Disability in Multiple Sclerosis

Ocrelizumab, a humanized anti-CD20 immunoglobulin G (IgG) antibody, may effectively control the risk of relapse and disability worsening in patients with multiple sclerosis (MS), according…

View More Ocrelizumab Beneficial for Relapse Risk and Disability in Multiple Sclerosis